Omarigliptin, also called MA-3102, is an selective inhibitor of DPP-4 with IC50 of 1.6 nM and Ki of 0.8 nM. Its selectivity is higher than other 168 proteasomes.

Saxagliptin is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.

Glibenclamide is a sulfonylurea compound that modulates insulin production.

Gliquidone is an ATP-sensitive K+ channel antagonist with IC50 of 27.2 nM.

Irbesartan is a selective and competitive nonpeptide angiotensin II antagonist with antihypertensive activity.

Glimepiride is a sulfonylurea which inhibit KATP with IC50 of 3.0 nM in pancreatic β-cells with fewer cardiac actions. It is used in the treatment of type 2 diabetes mellitus.

Gliclazide is a blocker of pancreatic β-cell ATP-sensitive potassium channels with IC50 of 184 nM in murine. It belongs to the sulfonylurea class of insulin secretagoguesIt. Gliclazide is an antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

Mitiglinide calcium is a drug for the treatment of type 2 diabetes and it is a highly selective KATP channel antagonist.

Repaglinide is a carbamoylmethyl benzoic acid (CMBA) derivative, which recently has become available for the treatment of type II diabetes.

OLDA is an agonist of endogenous vanilloid TRPV1 (VR1) receptor with EC50 of 36 nM and low affinity for rCB1 receptors (Ki = 1.6 μM).

Glipizide is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes.

Troglitazone is a PPARγ agonist with EC50 of 780 nM in murine and 555 nM in human. It has no activity at PPARα or PPARδ and can act as an anti-diabetic agent.

Voglibose, an N-substituted derivative of valiolamine, can inhibit α-glucosidase and be used to treat hyperglycemia and its concomitant diseases.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

AMG-3969 is a glucokinase-GKRP disruptor with IC50 value of 343nM and potently reverses the inhibitory effect of GKRP on GK activity.

GW9508 is selective FFA1 (GPR40) agonist with pEC50 of 7.32 and stimulates insulin secretion in a glucose-sensitive manner.

SB756050 is an agonist of selective TGR5 and has the potential treatment of type 2 diabetes.

AS 1269574 is a GPR119 receptor agonist with EC50 of 2.5 μM in HEK293 cells expressing human GPR119.

MBX-2982 is a selective, orally-available GPR119 agonist for the treatment of type 2 tiabetes.

Acarbose is an intestinal alpha-glucosidase inhibitor and can be used to treat type 2 diebetes.